Scott shares 50 diverse links covering topics from AI developments to policy changes, with commentary on current events, research findings, and societal trends. Longer summary

In this monthly links roundup, Scott Alexander covers a wide range of topics including AI developments, public policy changes, scientific research, and current events. The post follows a numbered format presenting each item with Scott's characteristic analysis and often humorous commentary. Notable topics include AI safety developments, changes in government policy, climate change updates, and various social and technological trends. The tone alternates between analytical and personal reflection, particularly when discussing potentially concerning political developments. Shorter summary

Scott Alexander and 1DaySooner outline potential positive health policy initiatives that could emerge under three key Trump administration health appointees: Jim O'Neill, Marty Makary, and Jay Bhattacharya. Longer summary

This post discusses potential health policy proposals under a hypothetical second Trump administration, focusing on three key appointees and their possible initiatives. The piece examines Jim O'Neill as Deputy Secretary of HHS, highlighting his potential work on organ donation compensation and longevity research; Marty Makary as FDA Commissioner, discussing FDA transparency and regulatory improvements; and Jay Bhattacharya as NIH Director, exploring research funding reforms and challenge trials. Written in collaboration with 1DaySooner, the post specifically focuses on optimistic scenarios that could emerge from these appointments. Shorter summary

The post explores the Far Out Initiative's goal to eliminate suffering through biotechnology, inspired by a pain-free woman and David Pearce's philosophy. Longer summary

This post discusses the Far Out Initiative, a project aimed at eliminating suffering through biotechnology. It begins by introducing Jo Cameron, a woman genetically incapable of feeling pain or anxiety, and explores the philosophical implications of her condition. The post then delves into David Pearce's suffering abolitionism philosophy and his practical approaches to ending suffering. Finally, it describes the Far Out Initiative's current efforts, led by Marcin Kowrygo, to create suffering-free animals through genetic engineering and potentially extend this to humans in the future. Shorter summary

Scott Alexander shares reader comments on his California ballot recommendations, updating some of his views and providing additional context on various races and propositions. Longer summary

This post highlights comments on Scott Alexander's California ballot recommendations. It covers various topics including Prop 31's impact on vaping, the Service Employees International Union's tactics regarding dialysis regulations, Newsom's campaign spending, Oakland mayoral race, and other ballot measures. Scott also updates some of his recommendations based on reader input, particularly for the Attorney General race. Shorter summary

Scott responds to various comments on his article about supplement labeling, addressing concerns about the industry and providing additional context and analysis. Longer summary

This post is a highlights reel of comments on Scott's previous article about supplement labeling. It covers various points raised by commenters, including skepticism about the supplement industry, concerns about heavy metal contamination, and a defense from the founder of LabDoor. Scott responds to each comment, providing additional context, analysis, and sometimes his own perspective on the issues raised. The post touches on topics such as the efficacy of supplements, the trustworthiness of supplement testing companies, and the potential risks associated with certain types of supplements. Shorter summary

Scott Alexander reviews comments on his posts about aducanumab and the FDA, acknowledging some mistakes while defending his overall critique of FDA conservatism. Longer summary

Scott Alexander reviews comments on his recent posts about aducanumab and the FDA. He acknowledges some mistakes in his original post, but defends his overall critique of the FDA as overly conservative. The comments cover various aspects of drug approval, including the aducanumab controversy, surrogate endpoints, the FDA's impact on small biotech companies, and comparisons to other regulatory systems. Scott reflects on how to improve his fact-checking process while still writing passionate pieces. Shorter summary

Scott Alexander examines the treatment for progeria and its potential implications for understanding and treating normal aging processes. Longer summary

This post discusses the implications of progeria treatments for understanding normal aging. Scott Alexander explores the recent FDA approval of lornafarnib for Hutchinson-Gilford Progeria Syndrome and its potential relevance to normal aging processes. He explains the cellular mechanisms behind progeria, involving defective lamin A protein production, and how this leads to accelerated aging through DNA damage accumulation. While initially concluding that lornafarnib might not help prevent normal aging, Scott then presents research suggesting that similar protein defects might play a role in normal aging processes. The post ends with uncertainty about the extent to which these mechanisms contribute to regular aging. Shorter summary

Scott Alexander summarizes reader comments about CBT-i apps, their effectiveness, pricing challenges, and FDA regulation. Longer summary

This post highlights key comments from readers on the topic of CBT-i (Cognitive Behavioral Therapy for insomnia) apps. Scott Alexander summarizes several lower-cost CBT-i apps that readers pointed out, including Night Owl, Sleepedy, and Dozy. He also mentions a highly recommended CBT-i book. The post then addresses questions about the effectiveness of CBT-i, citing studies that show it works as well as or better than medications. Finally, it discusses challenges in the app economy, FDA regulation of health apps, and includes insights from experts in the field. Shorter summary

Scott Alexander criticizes the emergence of expensive, prescription-only therapy apps, using Somryst (a CBT-i app) as an example, and warns about the normalization of this trend. Longer summary

Scott Alexander discusses the emergence of prescription-only apps, focusing on Somryst, a CBT-i app for insomnia. He criticizes the high cost ($899) and prescription requirement, arguing that it defeats the purpose of making therapy more accessible. The post explains how the US healthcare system incentivizes this model, comparing it to prescription fish oil. Scott expresses disappointment in the lack of affordable alternatives and warns that this trend might become normalized, urging readers to act while they still feel outraged by it. Shorter summary

Scott Alexander investigates the optimal dosage of Lexapro, comparing it to other antidepressants and exploring the reasons behind its effectiveness at lower doses. Longer summary

Scott Alexander explores the question of the right dose for Lexapro (escitalopram), an antidepressant. He examines official recommendations, compares Lexapro to other SSRIs, and investigates why Lexapro might be effective at lower doses. The post delves into studies on antidepressant dosing, the unique properties of Lexapro, and the potential benefits and risks of higher doses. Scott concludes that while there's no strong evidence for high doses of any antidepressant being more effective, prescribing higher doses of Lexapro might be as safe as other SSRIs and potentially more beneficial in some cases. Shorter summary

Scott Alexander explores the history and mechanism of DNP, a dangerous but effective weight-loss drug, and discusses recent developments in safer mitochondrial uncoupling agents. Longer summary

Scott Alexander discusses 2,4-dinitrophenol (DNP), a controversial and dangerous weight-loss drug that works by uncoupling mitochondria. He traces its history from the 1930s to modern times, explaining its effectiveness and severe side effects. The post then explores recent developments in mitochondrial uncoupling research, including potential safer alternatives and therapeutic applications beyond weight loss. Shorter summary

Scott Alexander critiques the FDA approval of esketamine for depression, discussing issues with drug development, efficacy, cost, and administration requirements. Longer summary

This post discusses the FDA's approval of esketamine for treatment-resistant depression, highlighting the issues with the pharmaceutical industry's approach to drug development and approval. Scott Alexander explains how companies often make minor changes to existing chemicals to patent them, as in the case of esketamine (a left-handed version of ketamine). He critiques the high cost of esketamine compared to regular ketamine and the FDA's stringent requirements for its administration. The post also questions the efficacy of esketamine based on clinical trials and discusses the inconvenience of the approved delivery method. Scott expresses disappointment that this approval may set a precedent for future psychedelic medicines, making them equally inconvenient and bureaucratic to access. Shorter summary

Scott Alexander offers various strategies for obtaining affordable mental health care and medication in the US, including discount programs, therapy alternatives, and supplement options. Longer summary

This post provides detailed advice on how to access mental health care and medication on a budget in the US. Scott outlines various strategies for obtaining prescription medications at lower costs, including using discount websites, pill splitting, and patient assistance programs. He also discusses affordable therapy options and supplement alternatives to prescription drugs. The post is aimed at those who don't qualify for government assistance and includes both legal and potentially legal methods. Scott emphasizes that this is not medical advice and should be used at one's own risk. Shorter summary

Scott Alexander shares a diverse collection of interesting links covering topics from architecture to AI, with brief summaries and occasional humorous commentary. Longer summary

This post is a collection of links to various interesting articles and news items. It covers a wide range of topics including architecture, Chinese immigrant history, psychotherapy, AI advancements, genetics, politics, science, and economics. The post includes brief summaries or comments on each link, often with a touch of humor or irony. Some notable items include discussions on the repressive climate in the Bay Area, new studies on autism and transgender links, and economists' opinions on Net Neutrality repeal. Shorter summary

Scott Alexander argues that the 33% rate of post-marketing safety events for FDA-approved drugs is not necessarily concerning and explains why post-marketing surveillance is a normal part of drug safety monitoring. Longer summary

Scott Alexander discusses a study showing that 33% of FDA-approved drugs in the past decade have faced post-marketing safety events. He argues that this doesn't necessarily mean the FDA is too lax, explaining that post-marketing surveillance is a normal and necessary part of drug safety monitoring. He points out that only 1.3% of drugs were actually withdrawn from the market, which he considers a good success rate. Scott explains why it's impossible to catch all potential side effects in pre-approval studies and gives examples of safety communications that range from important to seemingly trivial. He concludes that the 33% figure alone is meaningless without a broader cost-benefit analysis of FDA approval standards. Shorter summary

Scott argues against Vox's proposal for drug price controls, citing studies that such policies would significantly reduce pharmaceutical innovation and potentially cost millions of life-years long-term. Longer summary

Scott Alexander responds to Sarah Kliff's Vox article about drug pricing, arguing that her proposal for price controls on brand-name drugs would significantly decrease pharmaceutical innovation. He cites multiple economic studies suggesting price controls reduce R&D and new drug development. Scott argues that while price controls might lower costs in the short-term, they could cost millions of life-years long-term by reducing new drug creation. He suggests focusing on increasing generic drug competition and reducing unnecessary prescriptions of expensive brand-name drugs with cheap generic alternatives as better solutions to high drug prices. Shorter summary

Scott Alexander argues that the EpiPen price hike is due to over-regulation and cronyism in the pharmaceutical industry, not lack of regulation as suggested by Vox. Longer summary

This post criticizes Vox's article on EpiPen price hikes, arguing that the problem isn't lack of regulation but over-regulation and cronyism. Scott Alexander contrasts the pharmaceutical industry with the unregulated chair industry, pointing out that chair prices don't suddenly spike 400%. He then details how FDA regulations and patent laws prevent competitors from entering the EpiPen market, despite the drug being off-patent and inexpensive to produce. The post highlights several failed attempts by companies to create generic versions of EpiPens, and how lobbying by the manufacturer Mylan has helped maintain their monopoly. Scott uses an extended analogy comparing the situation to a hypothetical government-controlled chair market to illustrate the absurdity of the current system. Shorter summary

The post examines three major issues with generic medications: barriers to market entry, problematic FDA initiatives, and inconsistent pricing across pharmacies. Longer summary

This post discusses the problems with generic medications in the United States, focusing on three main issues. First, it explores why competitors don't easily emerge to challenge price gouging, using the example of Daraprim's price increase. The author suggests that FDA approval processes, including bioequivalence studies, create significant barriers to entry. Second, it critiques the FDA's Unapproved Drugs Initiative of 2006, which allowed companies to gain exclusive rights to public domain drugs by conducting studies, leading to price increases. Finally, it highlights the wide price disparities for generic drugs at different pharmacies, suggesting that comparison shopping can lead to significant savings. Shorter summary